Global Information
회사소개 | 문의 | 위시리스트

분석 툴 : 암 치료에서의 프로테인 키나아제 저해제

Protein Kinase Inhibitors in Oncology: Analytical Tool

리서치사 BioSeeker Group AB
발행일 2018년 12월 상품 코드 166080
페이지 정보 영문
US $ 4,450 ₩ 5,270,000 Desktop App plus Online Access to Updates (One Year) - Single User
US $ 8,900 ₩ 10,540,000 Desktop App plus Online Access to Updates (One Year) - Site License
US $ 13,350 ₩ 15,810,000 Desktop App plus Online Access to Updates (One Year) - Global License

분석 툴 : 암 치료에서의 프로테인 키나아제 저해제 Protein Kinase Inhibitors in Oncology: Analytical Tool
발행일 : 2018년 12월 페이지 정보 : 영문

종양학 분야에서 프로테인 키나아제 저해제(Protein Kinase Inhibitors)의 현재 및 새로운 약제에 관한 분석, 개발 기업 및 개발 프로젝트의 동향, 주요 임상시험 데이터 등을 전해드립니다.

    상품 구성(데이터베이스와 조사보고서의 패키지)
    • <조사보고서> 암의 프로테인 키나아제 치료(상품 코드 : 103311)
      • 제1장 개요
      • 제2장 암에 관하여
      • 제3장 조사 방법
      • 제4장 목차
      • 제5장 서론
      • 제6장 치료 효과를 최대한으로 하여 투자회수율을 높이기 위한 치료표적
        • 약제 리포지셔닝
        • 프로테인 키나아제 치료표적
        • 암 게놈 프로젝트와 프로테인 키나아제 치료표적
        • 프로테인 키나아제 치료의 구조 기반 약제 디자인
        • 특정된 프로테인 키나아제 치료표적간의 상호작용
        • 약제와 표적의 상호작용체(Interactome)
        • 경로 분석
      • 제7장 신제품의 대두
        • 종료된 약제표적 프로파일
        • 증록전 출시준비 단계
        • 제3상 임상시험
        • 제2상 임상시험
        • 제1상 임상시험
        • 전임상시험
        • 암 치료용 프로테인 키나아제 약제 개요
      • 제8장 화합물 전략 : 화합물별 프로테인 키나아제 치료제의 경쟁 벤치마킹
        • 소분자
        • 펩티드 및 프로테인 약제
        • 항체 및 항체 유사 구조(Antibody-like Structures)
        • 핵산 치료
        • 세포 및 유전자 치료
        • 프로테인 키나아제 치료의 근사성 경쟁
        • 프로테인 키나아제 치료표적의 서브 셀룰러 로컬리제이션에 입각한 화합물 전략
      • 제9장 프로테인 키나아제 치료제의 암에 대한 적용
        • 급성림프종백혈병
        • 급성골수성백혈병
        • 부신암
        • B세포림프종
        • 기저세포암
        • 양성 전립선 과형성
        • 담도암 외
      • 제10장 포트폴리오 플래닝
      • 제11장 면책사항
      • 제12장 약제 인덱스
      • 제13장 기업 인덱스
    • <데이터베이스> 암 치료제 파이프라인 : 프로테인키나아제 저해제(상품 코드 : 171785)
      • 임상시험 책임의사
      • 약제명 및 이명
        • 상표명
        • 제네릭약
        • 코드네임
      • 개발 단계
        • 개발중인 520개의 약제 최신 동향
        • 출시 완료
        • 등록 완료
        • 등록전
        • 제3상
        • 제2상
        • 제1상
        • 전임상
        • 데이터 없음
        • 중단
        • 중지
      • 적응
      • 표적
        • 187개의 표적을 45개로 분류
      • 표적 발현 프로파일
      • 경로
      • 메커니즘
      • 화합물
      • 약제 개요
        • 약제명
        • 임상시험 담당의사 및 파트너
        • 표적 및 표적의 분자 기능
        • 표적의 부위
        • 표적 발현 프로파일
        • 표적 시그널링 경로
        • 메커니즘
        • 개발 프로젝트
        • 약제 해설
        • 화합물 데이터
        • 특허 데이터
        • 비즈니스 및 시장
        • 제3상 데이터
        • 제2상 데이터
        • 제1상 데이터
        • 임상전 데이터
        • 라이선싱 정보
      • 응용 특성
      • 시스템 요건
        • Operating system: Windows (2000/XP/Vista/7/8) for Mac Users the service is only available online
        • Browser Application (Internet Explorer, Firefox, Chrome, Safari)
        • Internet access (to access related internet resources)
      ※개별 상품의 상세한 내용은 문의하여 주시기 바랍니다.
    ksm 11.03.15

    이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot of promise for more treatment successes in the future.

Protein Kinase Inhibitors in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your PKI drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Protein Kinase Inhibitors in Oncology: Analytical Tool achieves this by continuously scanning development in PKI and reporting:

  • Deals & Collaborations
  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
  • Funding/Grants/IPOs
  • Filings & Approvals
  • Latest Clinical Trial Development & Results
  • Newly launched clinical trials
  • Conference Coverage of the world's twelve leading meetings in oncology*
  • Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies
  • Target Novelty
  • Recent Funding
  • Early & Late Stage Pipeline
  • Biomarker/Companion Diagnostic Development (featured below)
  • Entered Deals & Alliances
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Choices (featured below)
  • Outcome of Clinical Trials
  • Indication Selection & Expansion Choices
  • Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your Protein Kinase Inhibitors in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your Protein Kinase Inhibitors in Oncology: Analytical Tool covers more than 508 companies plus partners who are today developing 1668 PKI drugs where of 940 are in active development in cancer across 322 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The Protein Kinase Inhibitors in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Protein Kinase Inhibitors in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top
전화 문의